Get the Stockscreener App
0.015
14.50%
0.0019
After Hours:
.02
0.005
+33.33%
Vincerx Pharma Inc stock is traded at $0.015, with a volume of 340.
It is up +14.50% in the last 24 hours and up +18.11% over the past month.
See More
Previous Close:
$0.0131
Open:
$0.015
24h Volume:
340
Relative Volume:
0.81
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-22.65M
P/E Ratio:
-0.00289
EPS:
-5.1849
Net Cash Flow:
$-22.84M
1W Performance:
+14.50%
1M Performance:
+18.11%
6M Performance:
+21.95%
1Y Performance:
-53.85%
1-Day Range:
$0.015
$0.015
1-Week Range:
$0.015
$0.015
52-Week Range:
$0.0101
$0.015
Vincerx Pharma Inc Stock (VINC) Company Profile
Compare VINC vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.015 | 0 | 0 | -22.65M | -22.84M | -5.1849 |
VRTX
Vertex Pharmaceuticals Inc
|
519.51 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.74 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
146.69 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.11 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-22 | Initiated | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-21 | Initiated | SVB Leerink | Outperform |
| Sep-13-21 | Initiated | Laidlaw | Buy |
| Aug-25-21 | Initiated | B. Riley Securities | Buy |
Vincerx Pharma Inc Stock (VINC) Latest News
Enterprise value to EBITDA forward of Vincerx Pharma, Inc. – OTC:VINC - TradingView
Price to book forward of Vincerx Pharma, Inc. – OTC:VINC - TradingView
Vincerx Pharma, Inc. Revenue Breakdown – OTC:VINC - TradingView
Vincerx Pharma Inc Actuals & Estimates (OTC:VINC) - TradingView
Why Is Vincerx Pharma, Inc. (VINCU) Stock Down Today? - Meyka
Drug Transport Company Sued by Insurer Over Destroyed-Cells Case - Bloomberg Law News
Vincerx Pharma, Inc. Announces Additional Adjournment of - globenewswire.com
Vincerx Pharma | DEFA14A: Others - Moomoo
At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News
VINCERX PHARMA (VINC) Stock Price, News & Analysis - Stock Titan
VINC Stock Price and Chart — OTC:VINC - TradingView
Nasdaq to delist Vincerx Pharma by April 23 - Investing.com Australia
vincerx pharma cancels merger, initiates wind-down activities By Investing.com - Investing.com India
vincerx pharma cancels merger, initiates wind-down activities - Investing.com
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down - Fierce Biotech
Financially struggling drugmaker's potential rescue falls apart. It now will wind down - bizjournals.com
Vincerx Pharma Inc. (VINC) reports earnings - qz.com
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis - Fierce Biotech
Cash-strapped Vincerx left mulling future after Oqory reverse merger falls apart - Fierce Biotech
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - Yahoo Finance
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Vincerx Pharma To Carry Out 1-for-20 Reverse Stock Split On January 28th, 2025 - moomoo.com
Vincerx Pharma, Inc. Announces Reverse Stock Split - The Manila Times
Vincerx Pharma enters at-the-market equity offering deal - Investing.com
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NE - GuruFocus
Chutes & Ladders—Vincerx acquisition leads to C-suite shake-up - Fierce Biotech
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - Asianet Newsable
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Yahoo Finance
Vincerx Pharma gets extension to meet Nasdaq listing criteria - Investing.com
ARMISTICE CAPITAL, LLC Expands Stake in Vincerx Pharma Inc - GuruFocus
Prosight Management, LP Reduces Stake in Vincerx Pharma Inc - GuruFocus
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - qz.com
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Vincerx Reports Positive Initial Clinical Data from Ongoing - GlobeNewswire
Vincerx Pharma (NASDAQ: VINCU)Share Price - intelligentinvestor.com.au
Vincerx Pharma Reports Second Quarter 2024 Financial Results - GlobeNewswire
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants By Investing.com - Investing.com India
Vincerx Blames Stock Plunge On Overheated ADC Expectations - Citeline News & Insights
Why Is Vincerx Pharma (VINC) Stock Down 64% Today? - InvestorPlace
Vincerx Pharma Presents Positive Preliminary Phase 1 Data - GlobeNewswire
Vincerx to Host Virtual Investor Event Reviewing - GlobeNewswire
Vincerx To Report VIP236 Trial Data Next Month - RTTNews
Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today? By Benzinga - Investing.com UK
Vincerx Pharma Announces Compelling Clinical Efficacy of - GlobeNewswire
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Ruth E. Stevens Net Worth (2026) - GuruFocus
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 - GlobeNewswire
Vincerx Pharma, Inc. (VINC) Dividend History, Date, and Yield - CoinCodex
Vincerx Pharma Inc Stock (VINC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
3.18%
Cap:
|
Volume (24h):